| Berberine — Berberine is a protoberberine/isoquinoline alkaloid natural product found in plants such as Coptis, Berberis, and Phellodendron. It is a small-molecule phytochemical with pleiotropic metabolic, anti-inflammatory, and anticancer signaling effects rather than a single highly selective target profile. Its standard abbreviation is BBR. In oncology it is best classified as a multitarget natural-product lead compound and adjunct-sensitizer candidate, with strong preclinical evidence but no established standard anticancer regulatory use. Its translational profile is shaped by very low conventional oral bioavailability, extensive first-pass metabolism, broad tissue distribution, and substantial context dependence between cancer-cell pro-death effects and normal-cell cytoprotective redox effects.
Primary mechanisms (ranked):
- AMPK-centered metabolic stress with mitochondrial dysfunction, ATP depletion, and apoptosis/autophagy induction
- Suppression of aerobic glycolysis and hypoxia signaling, including HIF-1α, GLUT1, HK2, LDHA, and PKM2-linked tumor metabolism
- Anti-proliferative cell-cycle control with cyclin/CDK suppression and tumor suppressor reactivation
- Inhibition of PI3K/AKT, MAPK/ERK, JAK/STAT, and NF-κB inflammatory-survival signaling
- Anti-metastatic and anti-EMT activity via Wnt/β-catenin, TGF-β/Smad, FAK/RhoA/ROCK, MMPs, and CXCR4-related programs
- Pro-oxidant mitochondrial ROS elevation and ER-stress/caspase signaling in many cancer models, with opposite antioxidant/NRF2-supportive effects in some normal-cell and non-cancer settings
- Context-dependent chemosensitization and radiosensitization, including effects on hypoxia signaling and DNA-repair competence
- Emerging ferroptosis-related activity in some tumor models, but not a universal dominant mechanism across berberine biology
Bioavailability / PK relevance: Conventional oral berberine has poor systemic bioavailability, often cited as below 1% in animal studies, because of limited absorption, P-glycoprotein efflux, first-pass intestinal/hepatic metabolism, and self-aggregation. Human exposure is usually in the low ng/mL plasma range with conventional dosing, while multiple metabolites may contribute to activity. Tissue distribution can exceed plasma levels, but PK remains a major clinical translation constraint.
In-vitro vs systemic exposure relevance: Many anticancer in-vitro studies use roughly 10–100 µM, commonly around 20–50 µM, which usually exceeds readily achievable conventional plasma exposure after standard oral dosing. Therefore, direct translation of cell-culture potency to systemic monotherapy expectations is limited unless local gut exposure, tissue accumulation, metabolite contribution, formulation enhancement, or combination use is specifically relevant.
Clinical evidence status: Strong preclinical and mechanistic evidence; limited early human oncology/chemoprevention evidence; no established phase III anticancer efficacy standard and no mainstream regulatory approval as an anticancer drug. Current clinical relevance is best viewed as investigational and adjunct-oriented rather than proven standalone oncology therapy.
Berberine is a chemical found in some plants like European barberry, goldenseal, goldthread, Oregon grape, phellodendron, and tree turmeric. Berberine is a bitter-tasting and yellow-colored chemical.
Coptis (commonly referring to Coptidis Rhizoma, a traditional Chinese medicinal herb) contains bioactive alkaloids (most notably berberine and coptisine) that have been studied for their pharmacological effects—including their influence on reactive oxygen species (ROS) and related pathways.
– Berberine is known for its relatively low oral bioavailability, often cited at less than 1%. This low bioavailability is mainly due to poor intestinal absorption and active efflux by transport proteins such as P-glycoprotein.
– Despite the low bioavailability, berberine is still pharmacologically active, and its metabolites may also contribute to its overall effects.
• Effective Dosage in Studies
– Many clinical trials or preclinical studies use dosages in the range of 500 to 1500 mg per day, typically administered in divided doses.
– Therefore, to obtain a bioactive dose of berberine, supplementation in a standardized extract form is necessary.
-IC50 in cancer cell lines: Approximately 10–100 µM (commonly around 20–50 µM in many models)
-IC50 in normal cell lines: Generally higher (often above 100 µM), although this can vary with cell type
- In vivo studies: Dosing regimens in animal models generally range from about 50 to 200 mg/kg
- very effective AChE inhibitor (Alzheimers)
- Berberine may enhance the effects of blood-thinning medications like warfarin and aspirin.
-Note half-life reports vary 2.5-90hrs?.
-low solubility of apigenin in water :
BioAv
Pathways:
- induce
ROS production
- ROS↑ related:
MMP↓(ΔΨm),
ER Stress↑,
Ca+2↑,
Cyt‑c↑,
Caspases↑,
DNA damage↑,
UPR↑,
cl-PARP↑,
HSP↓
- Lowers AntiOxidant defense in Cancer Cells:
NRF2↓,
GSH↓
- Raises
AntiOxidant
defense in Normal Cells:
NRF2↑,
SOD↑,
GSH↑,
Catalase↑,
- lowers
Inflammation :
NF-kB↓,
COX2↓,
p38↓, Pro-Inflammatory Cytokines :
IL-1β↓,
TNF-α↓,
IL-6↓,
IL-8↓
- PI3K/AKT(Inhibition), JAK/STATs, Wnt/β-catenin, AMPK, MAPK/ERK, and JNK.
- inhibit Growth/Metastases :
,
MMPs↓,
MMP2↓,
MMP9↓,
IGF-1↓,
uPA↓,
VEGF↓,
ROCK1↓,
FAK↓,
RhoA↓,
NF-κB↓,
CXCR4↓,
TGF-β↓,
α-SMA↓,
ERK↓
- reactivate genes thereby inhibiting cancer cell growth :
HDAC↓,
DNMT1↓,
EZH2↓,
P53↑,
HSP↓
- cause Cell cycle arrest :
TumCCA↑,
cyclin D1↓,
cyclin E↓,
CDK2↓,
CDK4↓,
CDK6↓,
- inhibits Migration/Invasion :
TumCMig↓,
TumCI↓,
FAK↓,
ERK↓,
- inhibits
glycolysis
/Warburg Effect and
ATP depletion :
HIF-1α↓,
PKM2↓,
cMyc↓,
GLUT1↓,
LDH↓,
LDHA↓,
HK2↓,
PFKs↓,
PDKs↓,
Glucose↓,
GlucoseCon↓
- inhibits
angiogenesis↓ :
VEGF↓,
HIF-1α↓,
Notch↓,
FGF↓,
PDGF↓,
EGFR↓,
Integrins↓,
- inhibits Cancer Stem Cells :
CSC↓,
Hh↓,
GLi1↓,
CD133↓,
β-catenin↓,
n-myc↓,
sox2↓,
notch2↓,
nestin↓,
OCT4↓,
- Others: PI3K↓,
AKT↓,
JAK↓,
STAT↓,
Wnt↓,
β-catenin↓,
AMPK↓,
α↓,
ERK↓,
JNK,
- Synergies:
chemo-sensitization,
chemoProtective,
RadioSensitizer,
RadioProtective,
Others(review target notes),
Neuroprotective,
Cognitive,
Renoprotection,
Hepatoprotective,
CardioProtective,
- Selectivity:
Cancer Cells vs Normal Cells
| Rank |
Pathway / Target Axis |
Direction |
Primary Effect |
Notes / Cancer Relevance |
Ref |
| 1 |
AMPK → mTOR axis |
↑ AMPK / ↓ mTOR signaling |
Metabolic stress + growth suppression |
In vivo/in vitro colon tumorigenesis model: berberine activates AMPK, inhibits mTOR signaling and reduces proliferation/tumorigenesis, growth suppression, autophagy, HIF-1α ↓, glycolysis ↓, berberine’s known mitochondrial/energetic effects |
(ref) |
| 2 |
Mitochondrial dysfunction / ROS generation |
↑ ROS / mitochondrial stress |
Upstream metabolic trigger |
Berberine inhibits mitochondrial function, increases ROS, and contributes to AMPK activation and downstream apoptosis |
(ref) |
| 3 |
Mitochondrial apoptosis (cytochrome c release) |
↑ cytochrome c release |
Intrinsic death signaling |
Oral cancer model: berberine reduces mitochondrial membrane potential, releases cytochrome c, activates caspase-3 |
(ref) |
| 4 |
Intrinsic apoptosis (caspase-3 activation) |
↑ caspase-3 activation |
Programmed cell death |
Same oral cancer study documents caspase-3 activation as a key execution marker |
(ref) |
| 5 |
NF-κB signaling (p65 activation) |
↓ NF-κB activation |
Reduced pro-survival transcription |
Colon cancer model reports inhibition of p65 phosphorylation; interpreted as secondary to metabolic/redox stress |
(ref) |
| 6 |
Cell cycle control |
↑ G1 arrest |
Proliferation blockade |
Prostate cancer model: berberine induces G1-phase cell cycle arrest and caspase-3–dependent apoptosis |
(ref) |
| 7 |
Hypoxia / glycolysis signaling (HIF-1α) |
↓ HIF-1α protein |
Warburg / glycolysis suppression |
Berberine suppresses mTOR and reduces HIF-1α protein expression downstream of AMPK activation |
(ref) |
| 8 |
Angiogenesis signaling (HIF-1α → VEGF axis) |
↓ VEGF signaling |
Reduced vascular support |
Lung cancer study: berberine suppresses VEGF signaling alongside HIF-1α inhibition |
(ref) |
| 9 |
PI3K–AKT–mTOR signaling |
↓ PI3K / AKT / mTOR |
Survival pathway suppression |
Gastric cancer paper: berberine represses PI3K/AKT/mTOR signaling and improves chemosensitivity |
(ref) |
| 10 |
Migration / invasion programs |
↓ migration & invasion |
Anti-metastatic phenotype |
Tongue SCC model: berberine suppresses migration and invasion with associated signaling changes |
(ref) |
| 11 |
Telomerase (hTERT) / immortalization axis |
↓ hTERT-related signaling |
Reduced proliferative capacity |
Lung cancer study includes AP-2/hTERT regulatory axis modulation by berberine |
(ref) |
| 12 |
In vivo tumor suppression |
↓ tumorigenesis |
Demonstrated anti-tumor effect |
Colon tumorigenesis model confirms reduced proliferation and tumor burden with berberine |
(ref) |
|